nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Pentagastrin—BCHE—multiple sclerosis	0.0129	1	CrCbGaD
Nafarelin—GNRHR—GPCRs, Other—S1PR1—multiple sclerosis	0.0129	0.07	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—CCR1—multiple sclerosis	0.0112	0.0609	CbGpPWpGaD
Nafarelin—GNRHR—brainstem—multiple sclerosis	0.00782	0.342	CbGeAlD
Nafarelin—GNRHR—Peptide GPCRs—CXCR3—multiple sclerosis	0.00743	0.0403	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—CCR2—multiple sclerosis	0.00723	0.0392	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—CXCR3—multiple sclerosis	0.0063	0.0342	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GPR65—multiple sclerosis	0.00584	0.0317	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—CNR1—multiple sclerosis	0.00566	0.0307	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—multiple sclerosis	0.00523	0.0284	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.0048	0.026	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—CCR5—multiple sclerosis	0.00466	0.0253	CbGpPWpGaD
Nafarelin—GNRHR—nervous system—multiple sclerosis	0.0041	0.179	CbGeAlD
Nafarelin—GNRHR—GPCRs, Other—CCR5—multiple sclerosis	0.00395	0.0214	CbGpPWpGaD
Nafarelin—GNRHR—central nervous system—multiple sclerosis	0.00395	0.173	CbGeAlD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.00387	0.021	CbGpPWpGaD
Nafarelin—GNRHR—cerebellum—multiple sclerosis	0.00386	0.169	CbGeAlD
Nafarelin—GNRHR—GPCR ligand binding—S1PR1—multiple sclerosis	0.00366	0.0198	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.00354	0.0192	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.00354	0.0192	CbGpPWpGaD
Nafarelin—GNRHR—brain—multiple sclerosis	0.00313	0.137	CbGeAlD
Nafarelin—GNRHR—GPCR ligand binding—GPR65—multiple sclerosis	0.00295	0.016	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL13—multiple sclerosis	0.0027	0.0146	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCR1—multiple sclerosis	0.0027	0.0146	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.00252	0.0137	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.00243	0.0132	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.00234	0.0127	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.00228	0.0124	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.00211	0.0114	CbGpPWpGaD
Nafarelin—Decreased appetite—Cladribine—multiple sclerosis	0.00207	0.00266	CcSEcCtD
Nafarelin—Mood swings—Dexamethasone—multiple sclerosis	0.00207	0.00265	CcSEcCtD
Nafarelin—Mood swings—Betamethasone—multiple sclerosis	0.00207	0.00265	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—S1PR1—multiple sclerosis	0.00207	0.0112	CbGpPWpGaD
Nafarelin—Weight increased—Prednisolone—multiple sclerosis	0.00206	0.00264	CcSEcCtD
Nafarelin—Constipation—Cladribine—multiple sclerosis	0.00204	0.00262	CcSEcCtD
Nafarelin—Sweating increased—Triamcinolone—multiple sclerosis	0.00203	0.0026	CcSEcCtD
Nafarelin—Increased appetite—Prednisone—multiple sclerosis	0.00202	0.0026	CcSEcCtD
Nafarelin—Myalgia—Azathioprine—multiple sclerosis	0.00202	0.00259	CcSEcCtD
Nafarelin—Arthralgia—Azathioprine—multiple sclerosis	0.00202	0.00259	CcSEcCtD
Nafarelin—Sweating increased—Methylprednisolone—multiple sclerosis	0.00202	0.00259	CcSEcCtD
Nafarelin—Dry skin—Betamethasone—multiple sclerosis	0.002	0.00257	CcSEcCtD
Nafarelin—Dry skin—Dexamethasone—multiple sclerosis	0.002	0.00257	CcSEcCtD
Nafarelin—Acute coronary syndrome—Prednisolone—multiple sclerosis	0.00199	0.00255	CcSEcCtD
Nafarelin—Neoplasm—Methotrexate—multiple sclerosis	0.00198	0.00254	CcSEcCtD
Nafarelin—Bladder pain—Methotrexate—multiple sclerosis	0.00198	0.00254	CcSEcCtD
Nafarelin—Myocardial infarction—Prednisolone—multiple sclerosis	0.00198	0.00253	CcSEcCtD
Nafarelin—Conjunctivitis—Prednisolone—multiple sclerosis	0.00196	0.00251	CcSEcCtD
Nafarelin—Gynaecomastia—Methotrexate—multiple sclerosis	0.00196	0.00251	CcSEcCtD
Nafarelin—Alopecia—Mitoxantrone—multiple sclerosis	0.00195	0.0025	CcSEcCtD
Nafarelin—Muscular weakness—Betamethasone—multiple sclerosis	0.00193	0.00247	CcSEcCtD
Nafarelin—Muscular weakness—Dexamethasone—multiple sclerosis	0.00193	0.00247	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CCL3—multiple sclerosis	0.00192	0.0104	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.0019	0.0103	CbGpPWpGaD
Nafarelin—Urticaria—Cladribine—multiple sclerosis	0.00189	0.00243	CcSEcCtD
Nafarelin—Weight increased—Triamcinolone—multiple sclerosis	0.00189	0.00243	CcSEcCtD
Nafarelin—Weight increased—Methylprednisolone—multiple sclerosis	0.00189	0.00242	CcSEcCtD
Nafarelin—Dysgeusia—Mitoxantrone—multiple sclerosis	0.00188	0.00241	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—S1PR1—multiple sclerosis	0.00188	0.0102	CbGpPWpGaD
Nafarelin—Affect lability—Prednisone—multiple sclerosis	0.00187	0.0024	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—PTGER4—multiple sclerosis	0.00185	0.01	CbGpPWpGaD
Nafarelin—Sweating increased—Dexamethasone—multiple sclerosis	0.00184	0.00236	CcSEcCtD
Nafarelin—Sweating increased—Betamethasone—multiple sclerosis	0.00184	0.00236	CcSEcCtD
Nafarelin—Acute coronary syndrome—Triamcinolone—multiple sclerosis	0.00183	0.00234	CcSEcCtD
Nafarelin—Acute coronary syndrome—Methylprednisolone—multiple sclerosis	0.00182	0.00234	CcSEcCtD
Nafarelin—Myocardial infarction—Triamcinolone—multiple sclerosis	0.00182	0.00233	CcSEcCtD
Nafarelin—Myocardial infarction—Methylprednisolone—multiple sclerosis	0.00181	0.00233	CcSEcCtD
Nafarelin—Conjunctivitis—Triamcinolone—multiple sclerosis	0.0018	0.00231	CcSEcCtD
Nafarelin—Mood swings—Prednisone—multiple sclerosis	0.0018	0.00231	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CXCR3—multiple sclerosis	0.00179	0.00969	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.00177	0.00227	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—RGS1—multiple sclerosis	0.00176	0.00953	CbGpPWpGaD
Nafarelin—Epistaxis—Triamcinolone—multiple sclerosis	0.00175	0.00224	CcSEcCtD
Nafarelin—Dry skin—Prednisone—multiple sclerosis	0.00174	0.00223	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CCR2—multiple sclerosis	0.00174	0.00942	CbGpPWpGaD
Nafarelin—Weight increased—Dexamethasone—multiple sclerosis	0.00172	0.0022	CcSEcCtD
Nafarelin—Weight increased—Betamethasone—multiple sclerosis	0.00172	0.0022	CcSEcCtD
Nafarelin—Asthenia—Cladribine—multiple sclerosis	0.00171	0.00219	CcSEcCtD
Nafarelin—Weight decreased—Betamethasone—multiple sclerosis	0.00171	0.00219	CcSEcCtD
Nafarelin—Weight decreased—Dexamethasone—multiple sclerosis	0.00171	0.00219	CcSEcCtD
Nafarelin—Pruritus—Cladribine—multiple sclerosis	0.00169	0.00216	CcSEcCtD
Nafarelin—Muscular weakness—Prednisone—multiple sclerosis	0.00168	0.00215	CcSEcCtD
Nafarelin—Rhinitis—Triamcinolone—multiple sclerosis	0.00167	0.00214	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—GPR65—multiple sclerosis	0.00167	0.00904	CbGpPWpGaD
Nafarelin—Rhinitis—Methylprednisolone—multiple sclerosis	0.00167	0.00214	CcSEcCtD
Nafarelin—Convulsion—Mitoxantrone—multiple sclerosis	0.00166	0.00213	CcSEcCtD
Nafarelin—Acute coronary syndrome—Dexamethasone—multiple sclerosis	0.00166	0.00213	CcSEcCtD
Nafarelin—Acute coronary syndrome—Betamethasone—multiple sclerosis	0.00166	0.00213	CcSEcCtD
Nafarelin—Abdominal distension—Prednisone—multiple sclerosis	0.00165	0.00212	CcSEcCtD
Nafarelin—Myocardial infarction—Betamethasone—multiple sclerosis	0.00165	0.00211	CcSEcCtD
Nafarelin—Myocardial infarction—Dexamethasone—multiple sclerosis	0.00165	0.00211	CcSEcCtD
Nafarelin—Conjunctivitis—Dexamethasone—multiple sclerosis	0.00164	0.0021	CcSEcCtD
Nafarelin—Conjunctivitis—Betamethasone—multiple sclerosis	0.00164	0.0021	CcSEcCtD
Nafarelin—Arthralgia—Mitoxantrone—multiple sclerosis	0.00164	0.0021	CcSEcCtD
Nafarelin—Chest pain—Mitoxantrone—multiple sclerosis	0.00164	0.0021	CcSEcCtD
Nafarelin—Myalgia—Mitoxantrone—multiple sclerosis	0.00164	0.0021	CcSEcCtD
Nafarelin—Diarrhoea—Cladribine—multiple sclerosis	0.00163	0.00209	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.00163	0.00885	CbGpPWpGaD
Nafarelin—Cerebrovascular accident—Methotrexate—multiple sclerosis	0.00162	0.00208	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CNR1—multiple sclerosis	0.0016	0.0087	CbGpPWpGaD
Nafarelin—Sweating increased—Prednisone—multiple sclerosis	0.0016	0.00205	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—RGS1—multiple sclerosis	0.0016	0.00866	CbGpPWpGaD
Nafarelin—Dizziness—Cladribine—multiple sclerosis	0.00158	0.00202	CcSEcCtD
Nafarelin—Oedema—Mitoxantrone—multiple sclerosis	0.00157	0.00201	CcSEcCtD
Nafarelin—Shock—Mitoxantrone—multiple sclerosis	0.00154	0.00198	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CCR1—multiple sclerosis	0.00152	0.00826	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL13—multiple sclerosis	0.00152	0.00826	CbGpPWpGaD
Nafarelin—Vomiting—Cladribine—multiple sclerosis	0.00152	0.00194	CcSEcCtD
Nafarelin—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.00152	0.00194	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—GPR65—multiple sclerosis	0.00151	0.00821	CbGpPWpGaD
Nafarelin—Mood swings—Methotrexate—multiple sclerosis	0.00151	0.00193	CcSEcCtD
Nafarelin—Rash—Cladribine—multiple sclerosis	0.0015	0.00193	CcSEcCtD
Nafarelin—Dermatitis—Cladribine—multiple sclerosis	0.0015	0.00193	CcSEcCtD
Nafarelin—Weight increased—Prednisone—multiple sclerosis	0.0015	0.00192	CcSEcCtD
Nafarelin—Anorexia—Mitoxantrone—multiple sclerosis	0.00149	0.00192	CcSEcCtD
Nafarelin—Headache—Cladribine—multiple sclerosis	0.00149	0.00192	CcSEcCtD
Nafarelin—Weight decreased—Prednisone—multiple sclerosis	0.00149	0.00191	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.00147	0.00797	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LINGO1—multiple sclerosis	0.00146	0.00793	CbGpPWpGaD
Nafarelin—Depression—Prednisone—multiple sclerosis	0.00146	0.00187	CcSEcCtD
Nafarelin—Mental disorder—Methylprednisolone—multiple sclerosis	0.00146	0.00187	CcSEcCtD
Nafarelin—Malnutrition—Methylprednisolone—multiple sclerosis	0.00145	0.00185	CcSEcCtD
Nafarelin—Acute coronary syndrome—Prednisone—multiple sclerosis	0.00144	0.00185	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CXCL10—multiple sclerosis	0.00144	0.00783	CbGpPWpGaD
Nafarelin—Myocardial infarction—Prednisone—multiple sclerosis	0.00144	0.00184	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.00143	0.00183	CcSEcCtD
Nafarelin—Dysgeusia—Triamcinolone—multiple sclerosis	0.00142	0.00182	CcSEcCtD
Nafarelin—Nausea—Cladribine—multiple sclerosis	0.00142	0.00182	CcSEcCtD
Nafarelin—Vertigo—Prednisolone—multiple sclerosis	0.00142	0.00182	CcSEcCtD
Nafarelin—Paraesthesia—Mitoxantrone—multiple sclerosis	0.00141	0.0018	CcSEcCtD
Nafarelin—Dyspnoea—Mitoxantrone—multiple sclerosis	0.0014	0.00179	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CCR1—multiple sclerosis	0.00138	0.0075	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL13—multiple sclerosis	0.00138	0.0075	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.00138	0.00748	CbGpPWpGaD
Nafarelin—Convulsion—Prednisolone—multiple sclerosis	0.00137	0.00175	CcSEcCtD
Nafarelin—Decreased appetite—Mitoxantrone—multiple sclerosis	0.00136	0.00175	CcSEcCtD
Nafarelin—Constipation—Mitoxantrone—multiple sclerosis	0.00134	0.00172	CcSEcCtD
Nafarelin—Alopecia—Dexamethasone—multiple sclerosis	0.00133	0.00171	CcSEcCtD
Nafarelin—Alopecia—Betamethasone—multiple sclerosis	0.00133	0.00171	CcSEcCtD
Nafarelin—Diarrhoea—Azathioprine—multiple sclerosis	0.00133	0.0017	CcSEcCtD
Nafarelin—Vertigo—Triamcinolone—multiple sclerosis	0.0013	0.00167	CcSEcCtD
Nafarelin—Vertigo—Methylprednisolone—multiple sclerosis	0.0013	0.00167	CcSEcCtD
Nafarelin—Oedema—Prednisolone—multiple sclerosis	0.00129	0.00165	CcSEcCtD
Nafarelin—Dysuria—Methotrexate—multiple sclerosis	0.00128	0.00165	CcSEcCtD
Nafarelin—Dizziness—Azathioprine—multiple sclerosis	0.00128	0.00164	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TAGAP—multiple sclerosis	0.00127	0.00688	CbGpPWpGaD
Nafarelin—Shock—Prednisolone—multiple sclerosis	0.00127	0.00162	CcSEcCtD
Nafarelin—Convulsion—Triamcinolone—multiple sclerosis	0.00126	0.00161	CcSEcCtD
Nafarelin—Convulsion—Methylprednisolone—multiple sclerosis	0.00125	0.00161	CcSEcCtD
Nafarelin—Urticaria—Mitoxantrone—multiple sclerosis	0.00125	0.0016	CcSEcCtD
Nafarelin—Hyperhidrosis—Prednisolone—multiple sclerosis	0.00124	0.00159	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CCL5—multiple sclerosis	0.00124	0.00674	CbGpPWpGaD
Nafarelin—Myalgia—Triamcinolone—multiple sclerosis	0.00123	0.00158	CcSEcCtD
Nafarelin—Vomiting—Azathioprine—multiple sclerosis	0.00123	0.00158	CcSEcCtD
Nafarelin—Myalgia—Methylprednisolone—multiple sclerosis	0.00123	0.00158	CcSEcCtD
Nafarelin—Arthralgia—Methylprednisolone—multiple sclerosis	0.00123	0.00158	CcSEcCtD
Nafarelin—Rash—Azathioprine—multiple sclerosis	0.00122	0.00157	CcSEcCtD
Nafarelin—Dermatitis—Azathioprine—multiple sclerosis	0.00122	0.00157	CcSEcCtD
Nafarelin—Depression—Methotrexate—multiple sclerosis	0.00122	0.00157	CcSEcCtD
Nafarelin—Headache—Azathioprine—multiple sclerosis	0.00121	0.00156	CcSEcCtD
Nafarelin—Conjunctivitis—Methotrexate—multiple sclerosis	0.00119	0.00153	CcSEcCtD
Nafarelin—Oedema—Triamcinolone—multiple sclerosis	0.00118	0.00152	CcSEcCtD
Nafarelin—Vertigo—Dexamethasone—multiple sclerosis	0.00118	0.00151	CcSEcCtD
Nafarelin—Vertigo—Betamethasone—multiple sclerosis	0.00118	0.00151	CcSEcCtD
Nafarelin—Shock—Triamcinolone—multiple sclerosis	0.00116	0.00149	CcSEcCtD
Nafarelin—Insomnia—Prednisolone—multiple sclerosis	0.00116	0.00149	CcSEcCtD
Nafarelin—Alopecia—Prednisone—multiple sclerosis	0.00116	0.00149	CcSEcCtD
Nafarelin—Shock—Methylprednisolone—multiple sclerosis	0.00116	0.00149	CcSEcCtD
Nafarelin—Epistaxis—Methotrexate—multiple sclerosis	0.00116	0.00148	CcSEcCtD
Nafarelin—Paraesthesia—Prednisolone—multiple sclerosis	0.00115	0.00148	CcSEcCtD
Nafarelin—Mental disorder—Prednisone—multiple sclerosis	0.00115	0.00148	CcSEcCtD
Nafarelin—Nausea—Azathioprine—multiple sclerosis	0.00115	0.00148	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.00115	0.00623	CbGpPWpGaD
Nafarelin—Malnutrition—Prednisone—multiple sclerosis	0.00115	0.00147	CcSEcCtD
Nafarelin—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.00114	0.00147	CcSEcCtD
Nafarelin—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00114	0.00146	CcSEcCtD
Nafarelin—Convulsion—Betamethasone—multiple sclerosis	0.00114	0.00146	CcSEcCtD
Nafarelin—Convulsion—Dexamethasone—multiple sclerosis	0.00114	0.00146	CcSEcCtD
Nafarelin—Asthenia—Mitoxantrone—multiple sclerosis	0.00112	0.00144	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.00112	0.0061	CbGpPWpGaD
Nafarelin—Myalgia—Betamethasone—multiple sclerosis	0.00112	0.00144	CcSEcCtD
Nafarelin—Myalgia—Dexamethasone—multiple sclerosis	0.00112	0.00144	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CCR5—multiple sclerosis	0.00112	0.00607	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—S1PR1—multiple sclerosis	0.00111	0.00601	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GPC5—multiple sclerosis	0.00108	0.00585	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00108	0.00138	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00108	0.00138	CcSEcCtD
Nafarelin—Oedema—Betamethasone—multiple sclerosis	0.00107	0.00138	CcSEcCtD
Nafarelin—Oedema—Dexamethasone—multiple sclerosis	0.00107	0.00138	CcSEcCtD
Nafarelin—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00107	0.00138	CcSEcCtD
Nafarelin—Insomnia—Triamcinolone—multiple sclerosis	0.00107	0.00137	CcSEcCtD
Nafarelin—Insomnia—Methylprednisolone—multiple sclerosis	0.00107	0.00137	CcSEcCtD
Nafarelin—Paraesthesia—Triamcinolone—multiple sclerosis	0.00106	0.00136	CcSEcCtD
Nafarelin—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00106	0.00136	CcSEcCtD
Nafarelin—Shock—Betamethasone—multiple sclerosis	0.00106	0.00135	CcSEcCtD
Nafarelin—Shock—Dexamethasone—multiple sclerosis	0.00106	0.00135	CcSEcCtD
Nafarelin—Dyspnoea—Triamcinolone—multiple sclerosis	0.00105	0.00135	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PTGER4—multiple sclerosis	0.00104	0.00567	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Betamethasone—multiple sclerosis	0.00104	0.00133	CcSEcCtD
Nafarelin—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.00104	0.00133	CcSEcCtD
Nafarelin—Vertigo—Prednisone—multiple sclerosis	0.00103	0.00132	CcSEcCtD
Nafarelin—Anorexia—Dexamethasone—multiple sclerosis	0.00102	0.00131	CcSEcCtD
Nafarelin—Anorexia—Betamethasone—multiple sclerosis	0.00102	0.00131	CcSEcCtD
Nafarelin—Urticaria—Prednisolone—multiple sclerosis	0.00102	0.00131	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CXCR3—multiple sclerosis	0.00101	0.00547	CbGpPWpGaD
Nafarelin—Vomiting—Mitoxantrone—multiple sclerosis	0.000997	0.00128	CcSEcCtD
Nafarelin—Convulsion—Prednisone—multiple sclerosis	0.000992	0.00127	CcSEcCtD
Nafarelin—Rash—Mitoxantrone—multiple sclerosis	0.000988	0.00127	CcSEcCtD
Nafarelin—Dermatitis—Mitoxantrone—multiple sclerosis	0.000988	0.00127	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CCL3—multiple sclerosis	0.000986	0.00535	CbGpPWpGaD
Nafarelin—Headache—Mitoxantrone—multiple sclerosis	0.000982	0.00126	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CCR2—multiple sclerosis	0.000982	0.00533	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000978	0.00125	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000978	0.00125	CcSEcCtD
Nafarelin—Myalgia—Prednisone—multiple sclerosis	0.000975	0.00125	CcSEcCtD
Nafarelin—Arthralgia—Prednisone—multiple sclerosis	0.000975	0.00125	CcSEcCtD
Nafarelin—Alopecia—Methotrexate—multiple sclerosis	0.000971	0.00125	CcSEcCtD
Nafarelin—Insomnia—Dexamethasone—multiple sclerosis	0.000971	0.00124	CcSEcCtD
Nafarelin—Insomnia—Betamethasone—multiple sclerosis	0.000971	0.00124	CcSEcCtD
Nafarelin—Paraesthesia—Betamethasone—multiple sclerosis	0.000964	0.00124	CcSEcCtD
Nafarelin—Paraesthesia—Dexamethasone—multiple sclerosis	0.000964	0.00124	CcSEcCtD
Nafarelin—Mental disorder—Methotrexate—multiple sclerosis	0.000963	0.00123	CcSEcCtD
Nafarelin—Malnutrition—Methotrexate—multiple sclerosis	0.000957	0.00123	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PTGER4—multiple sclerosis	0.000949	0.00515	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RGS1—multiple sclerosis	0.000942	0.00511	CbGpPWpGaD
Nafarelin—Urticaria—Triamcinolone—multiple sclerosis	0.00094	0.0012	CcSEcCtD
Nafarelin—Urticaria—Methylprednisolone—multiple sclerosis	0.000937	0.0012	CcSEcCtD
Nafarelin—Dysgeusia—Methotrexate—multiple sclerosis	0.000937	0.0012	CcSEcCtD
Nafarelin—Oedema—Prednisone—multiple sclerosis	0.000935	0.0012	CcSEcCtD
Nafarelin—Decreased appetite—Dexamethasone—multiple sclerosis	0.000933	0.0012	CcSEcCtD
Nafarelin—Decreased appetite—Betamethasone—multiple sclerosis	0.000933	0.0012	CcSEcCtD
Nafarelin—Nausea—Mitoxantrone—multiple sclerosis	0.000931	0.00119	CcSEcCtD
Nafarelin—Shock—Prednisone—multiple sclerosis	0.000919	0.00118	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CXCR3—multiple sclerosis	0.000916	0.00497	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CNR1—multiple sclerosis	0.000906	0.00491	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Prednisone—multiple sclerosis	0.000903	0.00116	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GPR65—multiple sclerosis	0.000893	0.00485	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCR2—multiple sclerosis	0.000891	0.00484	CbGpPWpGaD
Nafarelin—Anorexia—Prednisone—multiple sclerosis	0.000891	0.00114	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000877	0.00476	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—POMC—multiple sclerosis	0.000875	0.00475	CbGpPWpGaD
Nafarelin—Vertigo—Methotrexate—multiple sclerosis	0.00086	0.0011	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CCL2—multiple sclerosis	0.000856	0.00464	CbGpPWpGaD
Nafarelin—Urticaria—Dexamethasone—multiple sclerosis	0.000853	0.00109	CcSEcCtD
Nafarelin—Urticaria—Betamethasone—multiple sclerosis	0.000853	0.00109	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000851	0.00109	CcSEcCtD
Nafarelin—Dizziness—Prednisolone—multiple sclerosis	0.00085	0.00109	CcSEcCtD
Nafarelin—Asthenia—Triamcinolone—multiple sclerosis	0.000849	0.00109	CcSEcCtD
Nafarelin—Asthenia—Methylprednisolone—multiple sclerosis	0.000847	0.00109	CcSEcCtD
Nafarelin—Insomnia—Prednisone—multiple sclerosis	0.000845	0.00108	CcSEcCtD
Nafarelin—Paraesthesia—Prednisone—multiple sclerosis	0.000839	0.00108	CcSEcCtD
Nafarelin—Pruritus—Triamcinolone—multiple sclerosis	0.000837	0.00107	CcSEcCtD
Nafarelin—Pruritus—Methylprednisolone—multiple sclerosis	0.000835	0.00107	CcSEcCtD
Nafarelin—Convulsion—Methotrexate—multiple sclerosis	0.000829	0.00106	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CNR1—multiple sclerosis	0.000823	0.00446	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCR1—multiple sclerosis	0.000817	0.00443	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL13—multiple sclerosis	0.000817	0.00443	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000816	0.00442	CbGpPWpGaD
Nafarelin—Chest pain—Methotrexate—multiple sclerosis	0.000815	0.00104	CcSEcCtD
Nafarelin—Myalgia—Methotrexate—multiple sclerosis	0.000815	0.00104	CcSEcCtD
Nafarelin—Arthralgia—Methotrexate—multiple sclerosis	0.000815	0.00104	CcSEcCtD
Nafarelin—Decreased appetite—Prednisone—multiple sclerosis	0.000812	0.00104	CcSEcCtD
Nafarelin—Rash—Prednisolone—multiple sclerosis	0.000811	0.00104	CcSEcCtD
Nafarelin—Dermatitis—Prednisolone—multiple sclerosis	0.00081	0.00104	CcSEcCtD
Nafarelin—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000807	0.00104	CcSEcCtD
Nafarelin—Headache—Prednisolone—multiple sclerosis	0.000806	0.00103	CcSEcCtD
Nafarelin—Constipation—Prednisone—multiple sclerosis	0.000799	0.00102	CcSEcCtD
Nafarelin—Dizziness—Triamcinolone—multiple sclerosis	0.000782	0.001	CcSEcCtD
Nafarelin—Dizziness—Methylprednisolone—multiple sclerosis	0.00078	0.001	CcSEcCtD
Nafarelin—Asthenia—Betamethasone—multiple sclerosis	0.00077	0.000987	CcSEcCtD
Nafarelin—Asthenia—Dexamethasone—multiple sclerosis	0.00077	0.000987	CcSEcCtD
Nafarelin—Nausea—Prednisolone—multiple sclerosis	0.000764	0.00098	CcSEcCtD
Nafarelin—Pruritus—Betamethasone—multiple sclerosis	0.000759	0.000974	CcSEcCtD
Nafarelin—Pruritus—Dexamethasone—multiple sclerosis	0.000759	0.000974	CcSEcCtD
Nafarelin—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000755	0.000968	CcSEcCtD
Nafarelin—Vomiting—Triamcinolone—multiple sclerosis	0.000752	0.000964	CcSEcCtD
Nafarelin—Vomiting—Methylprednisolone—multiple sclerosis	0.00075	0.000962	CcSEcCtD
Nafarelin—Rash—Triamcinolone—multiple sclerosis	0.000746	0.000956	CcSEcCtD
Nafarelin—Dermatitis—Triamcinolone—multiple sclerosis	0.000745	0.000955	CcSEcCtD
Nafarelin—Anorexia—Methotrexate—multiple sclerosis	0.000745	0.000955	CcSEcCtD
Nafarelin—Rash—Methylprednisolone—multiple sclerosis	0.000744	0.000954	CcSEcCtD
Nafarelin—Dermatitis—Methylprednisolone—multiple sclerosis	0.000743	0.000953	CcSEcCtD
Nafarelin—Urticaria—Prednisone—multiple sclerosis	0.000742	0.000952	CcSEcCtD
Nafarelin—Headache—Triamcinolone—multiple sclerosis	0.000741	0.00095	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CXCL10—multiple sclerosis	0.000741	0.00402	CbGpPWpGaD
Nafarelin—Headache—Methylprednisolone—multiple sclerosis	0.000739	0.000948	CcSEcCtD
Nafarelin—Diarrhoea—Betamethasone—multiple sclerosis	0.000734	0.000941	CcSEcCtD
Nafarelin—Diarrhoea—Dexamethasone—multiple sclerosis	0.000734	0.000941	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000712	0.000912	CcSEcCtD
Nafarelin—Dizziness—Dexamethasone—multiple sclerosis	0.00071	0.00091	CcSEcCtD
Nafarelin—Dizziness—Betamethasone—multiple sclerosis	0.00071	0.00091	CcSEcCtD
Nafarelin—Insomnia—Methotrexate—multiple sclerosis	0.000706	0.000906	CcSEcCtD
Nafarelin—Nausea—Triamcinolone—multiple sclerosis	0.000703	0.000901	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CCL5—multiple sclerosis	0.000702	0.00381	CbGpPWpGaD
Nafarelin—Paraesthesia—Methotrexate—multiple sclerosis	0.000701	0.000899	CcSEcCtD
Nafarelin—Nausea—Methylprednisolone—multiple sclerosis	0.000701	0.000899	CcSEcCtD
Nafarelin—Dyspnoea—Methotrexate—multiple sclerosis	0.000696	0.000893	CcSEcCtD
Nafarelin—Vomiting—Dexamethasone—multiple sclerosis	0.000682	0.000875	CcSEcCtD
Nafarelin—Vomiting—Betamethasone—multiple sclerosis	0.000682	0.000875	CcSEcCtD
Nafarelin—Decreased appetite—Methotrexate—multiple sclerosis	0.000679	0.000871	CcSEcCtD
Nafarelin—Rash—Betamethasone—multiple sclerosis	0.000677	0.000868	CcSEcCtD
Nafarelin—Rash—Dexamethasone—multiple sclerosis	0.000677	0.000868	CcSEcCtD
Nafarelin—Dermatitis—Dexamethasone—multiple sclerosis	0.000676	0.000867	CcSEcCtD
Nafarelin—Dermatitis—Betamethasone—multiple sclerosis	0.000676	0.000867	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000674	0.00366	CbGpPWpGaD
Nafarelin—Headache—Betamethasone—multiple sclerosis	0.000672	0.000862	CcSEcCtD
Nafarelin—Headache—Dexamethasone—multiple sclerosis	0.000672	0.000862	CcSEcCtD
Nafarelin—Asthenia—Prednisone—multiple sclerosis	0.000671	0.00086	CcSEcCtD
Nafarelin—Pruritus—Prednisone—multiple sclerosis	0.000661	0.000848	CcSEcCtD
Nafarelin—Diarrhoea—Prednisone—multiple sclerosis	0.000639	0.00082	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CCL5—multiple sclerosis	0.000638	0.00346	CbGpPWpGaD
Nafarelin—Nausea—Dexamethasone—multiple sclerosis	0.000637	0.000817	CcSEcCtD
Nafarelin—Nausea—Betamethasone—multiple sclerosis	0.000637	0.000817	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CCR5—multiple sclerosis	0.000633	0.00343	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000623	0.00338	CbGpPWpGaD
Nafarelin—Urticaria—Methotrexate—multiple sclerosis	0.00062	0.000796	CcSEcCtD
Nafarelin—Dizziness—Prednisone—multiple sclerosis	0.000618	0.000792	CcSEcCtD
Nafarelin—Vomiting—Prednisone—multiple sclerosis	0.000594	0.000762	CcSEcCtD
Nafarelin—Rash—Prednisone—multiple sclerosis	0.000589	0.000756	CcSEcCtD
Nafarelin—Dermatitis—Prednisone—multiple sclerosis	0.000589	0.000755	CcSEcCtD
Nafarelin—Headache—Prednisone—multiple sclerosis	0.000585	0.000751	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CCL3—multiple sclerosis	0.000582	0.00316	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCR5—multiple sclerosis	0.000574	0.00312	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL2RA—multiple sclerosis	0.000566	0.00307	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTGER4—multiple sclerosis	0.00056	0.00304	CbGpPWpGaD
Nafarelin—Asthenia—Methotrexate—multiple sclerosis	0.00056	0.000719	CcSEcCtD
Nafarelin—Nausea—Prednisone—multiple sclerosis	0.000555	0.000712	CcSEcCtD
Nafarelin—Pruritus—Methotrexate—multiple sclerosis	0.000553	0.000709	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PGR—multiple sclerosis	0.000552	0.00299	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCR3—multiple sclerosis	0.000541	0.00294	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CD28—multiple sclerosis	0.000536	0.00291	CbGpPWpGaD
Nafarelin—Diarrhoea—Methotrexate—multiple sclerosis	0.000534	0.000685	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CCR2—multiple sclerosis	0.000527	0.00286	CbGpPWpGaD
Nafarelin—Dizziness—Methotrexate—multiple sclerosis	0.000516	0.000662	CcSEcCtD
Nafarelin—Vomiting—Methotrexate—multiple sclerosis	0.000497	0.000637	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—POMC—multiple sclerosis	0.000494	0.00268	CbGpPWpGaD
Nafarelin—Rash—Methotrexate—multiple sclerosis	0.000492	0.000631	CcSEcCtD
Nafarelin—Dermatitis—Methotrexate—multiple sclerosis	0.000492	0.000631	CcSEcCtD
Nafarelin—Headache—Methotrexate—multiple sclerosis	0.000489	0.000627	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CNR1—multiple sclerosis	0.000486	0.00264	CbGpPWpGaD
Nafarelin—Nausea—Methotrexate—multiple sclerosis	0.000464	0.000595	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—POMC—multiple sclerosis	0.000449	0.00244	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCL2—multiple sclerosis	0.000439	0.00238	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL10—multiple sclerosis	0.000438	0.00237	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—TYK2—multiple sclerosis	0.000399	0.00216	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CD86—multiple sclerosis	0.000383	0.00208	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL5—multiple sclerosis	0.000377	0.00204	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—IL2—multiple sclerosis	0.000365	0.00198	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SPP1—multiple sclerosis	0.000349	0.00189	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCR5—multiple sclerosis	0.000339	0.00184	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL2RA—multiple sclerosis	0.000334	0.00181	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL2—multiple sclerosis	0.000332	0.0018	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOE—multiple sclerosis	0.000309	0.00167	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CD80—multiple sclerosis	0.000279	0.00151	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—POMC—multiple sclerosis	0.000265	0.00144	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL2—multiple sclerosis	0.000259	0.00141	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAPK1—multiple sclerosis	0.000254	0.00138	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TYK2—multiple sclerosis	0.000236	0.00128	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL2—multiple sclerosis	0.000196	0.00106	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6—multiple sclerosis	0.000195	0.00106	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP9—multiple sclerosis	0.000186	0.00101	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT3—multiple sclerosis	0.000165	0.000895	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MYC—multiple sclerosis	0.000153	0.000832	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TGFB1—multiple sclerosis	0.000153	0.00083	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK1—multiple sclerosis	0.00015	0.000814	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6—multiple sclerosis	0.000115	0.000625	CbGpPWpGaD
